Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report

Table 1 Several previous reports of salvage brachytherapy

Study year	N	Prior RT	Use of ADT	Median f/u	Outcome	Adverse event	Prescribed dose
Koutrouveils* 2003 [1]	31	seed	Neo 3 mos except 1	30 mos	5 yr-bDFS: 87%	GI: G4 (2/31)	¹²⁵I:100-144 Gy ¹⁰³Pd:100-120 Gy
Wong 2006 [3]	17	EBRT	Neo 3 mos: 12 ad 6 mos: 5	44 mos	4 yr-bDFS: 75%	GU:G4 (1/17)	¹²⁵I:126 Gy in principle
Nguyen 2007 [4]	25	EBRT: 13 seed: 12	none	47 mos	4 yr-bDFS: 70%	GU: G3-4 13% GI: G3-4 30%	¹²⁵I:137 Gy
Lee 2007 [5]	21	EBRT	Concurrent -ad: 12	36 mos	5 yr-bDFS: 38%	G3 or over: none	¹²⁵I:90 Gy
Aaronson 2009 [6]	24	EBRT	Concurrent: 17%	30 mos	3 yr-bDFS: 89.5%	GU: G3 (1/24)	¹²⁵I:144 Gy (108 Gy)
Moman 2010 [7]	31	EBRT: 20 seed: 11	Neo 3 mos: 5	9.2 yrs	5 yr-FFbF: 23%	lateGU: G3 (6/31) lateGI: G3 (2/31)	¹²⁵I:145 Gy
Burri* 2010 [2]	37	EBRT: 32 seed: 5	Neo + ad 6 mos: 31	86 mos	5 yr-FFbF: 64.5%	GI: G4 (1/37)	¹²⁵I:135 Gy

*Report of brachytherapy for recurrence of seminal vesicle.
RT: Radiation Therapy, ADT: Androgen Deprivation Therapy, f/u: follow-up, EBRT : External Beam Radiation Therapy, Seed: Seed Implant (Brachytherapy), Neo: Neoadjuvant Therapy, Ad: Adjuvant Therapy, bDFS: biochemical Disease Free Survival, FFbF: Freedom From biochemical Failure, GI: Gastrointestinal adverse effect, GU: Genitourinary adverse effect, G: Grade.

ISSN: 1756-0500